Department of Neurology, Mayo Clinic, Rochester, MN, United States of America.
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States of America.
PLoS One. 2023 May 11;18(5):e0284182. doi: 10.1371/journal.pone.0284182. eCollection 2023.
Flortaucipir (FTP) PET is a key imaging technique to evaluate tau burden indirectly. However, it appears to have greater utility for 3R+4R tau found in Alzheimer's disease (AD), compared to other non-AD tauopathies. The purpose of this study is to determine how flortaucipir uptake links to neuropathologically determined tau burden in AD and non-AD tauopathies. We identified nine individuals who had undergone antemortem tau-PET and postmortem neuropathological analyses. The cohort included three patients with low, moderate, and high AD neuropathologic changes (ADNC), five patients with a non-AD tauopathy (one Pick's disease, three progressive supranuclear palsies, and one globular glial tauopathy), and one control without ADNC. We compared regional flortaucipir PET uptake with tau burden using an anti-AT8 antibody. There was a very good correlation between flortaucipir uptake and tau burden in those with ADNC although, in one ADNC patient, flortaucipir uptake and tau burden did not match due to the presence of argyrophilic grains disease. Non-AD patients showed lower flortaucipir uptake globally compared to ADNC patients. In the non-AD patients, some regional associations between flortaucipir uptake and histopathological tau burden were observed. Flortaucipir uptake is strongly linked to underlying tau burden in patients with ADNC but there are instances where they do not match. On-the-other hand, flortaucipir has a limited capacity to represent histopathological tau burden in non-AD patients although there are instances where regional uptake correlates with regional tau burden. There is a definite need for the development of future generations of tau-PET ligands that can detect non-AD tau.
氟脱氧酪氨酸（FTP）正电子发射断层扫描（PET）是一种间接评估 tau 负担的关键成像技术。然而，与其他非 AD tau 病相比，它似乎对阿尔茨海默病（AD）中发现的 3R+4R tau 更有用。本研究旨在确定氟脱氧酪氨酸摄取与 AD 和非 AD tau 病中神经病理学确定的 tau 负担之间的联系。我们确定了 9 名接受过 tau-PET 正电子发射断层扫描和死后神经病理学分析的个体。该队列包括 3 名 AD 神经病理学变化（ADNC）程度低、中、高的患者，5 名非 AD tau 病患者（1 名 Pick 病、3 名进行性核上性麻痹和 1 名球状神经胶质 tau 病），以及 1 名无 ADNC 的对照者。我们使用抗 AT8 抗体比较了区域氟脱氧酪氨酸 PET 摄取与 tau 负担。尽管在一名 ADNC 患者中，由于存在嗜银颗粒病，氟脱氧酪氨酸摄取和 tau 负担不匹配，但在有 ADNC 的患者中，氟脱氧酪氨酸摄取与 tau 负担之间存在很好的相关性。与 ADNC 患者相比，非 AD 患者的氟脱氧酪氨酸摄取总体上较低。在非 AD 患者中，观察到氟脱氧酪氨酸摄取与组织病理学 tau 负担之间存在一些区域相关性。在 ADNC 患者中，氟脱氧酪氨酸摄取与 tau 负担密切相关，但有些情况下两者并不匹配。另一方面，氟脱氧酪氨酸在非 AD 患者中检测 tau 的能力有限，但在某些情况下，区域摄取与区域 tau 负担相关。因此，迫切需要开发能够检测非 AD tau 的下一代 tau-PET 配体。
